SCHEMBL4684047

SCHEMBL4684047

Cc1ccccc1C(=O)NC(NC(=S)Nc1cccnc1)C(C)(C)C

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCC9 O60706 2/20 0.67
ABCC8 Q09428 2/20 0.67
KCNJ11 Q14654 2/20 0.67
KCNJ8 Q15842 2/20 0.67
KMT2A Q03164 5/20 0.54
MEN1 O00255 4/20 0.54
LMNA P02545 3/20 0.54
ALOX12 P18054 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
HTT P42858 2/20 0.52
ALDH1A1 P00352 4/20 0.49
MAPT P10636 2/20 0.49
TSHR P16473 1/20 0.47
CYP11B2 P19099 2/20 0.46
KDM4E B2RXH2 2/20 0.45
HPGD P15428 1/20 0.45
SGMS2 Q8NHU3 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
TYK2 P29597 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6671668 1.00 ABCC9 (0.67) ABCC9ABCC8KCNJ11KCNJ8KMT2A
SCHEMBL4682262 0.90 LMNA (0.67) ABCC9ABCC8KCNJ11KCNJ8KMT2A
SCHEMBL4682799 0.85 ABCC9 (0.82) ABCC9ABCC8KCNJ11KCNJ8KMT2A
SCHEMBL4682701 0.83 ABCC9 (0.82) ABCC9ABCC8KCNJ11KCNJ8KMT2A
SCHEMBL4682104 0.83 ABCC9 (0.82) ABCC9ABCC8KCNJ11KCNJ8KMT2A
SCHEMBL4678811 0.83 ABCC9 (0.82) ABCC9ABCC8KCNJ11KCNJ8KMT2A
SCHEMBL4684962 0.82 ABCC9 (0.47) ABCC9ABCC8KCNJ11KCNJ8KMT2A
SCHEMBL4684953 0.82 ABCC9 (0.47) ABCC9ABCC8KCNJ11KCNJ8KMT2A
SCHEMBL4682133 0.80 ABCC9 (1.00) ABCC9ABCC8KCNJ11KCNJ8KMT2A
SCHEMBL4682028 0.79 MEN1 (0.55) ABCC9ABCC8KCNJ11KCNJ8KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1198456-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2007-09-19 EP claimed
EP-1392655-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2004-03-03 EP claimed
US-6645968-B2 E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; ABBOTT LABORATORIES 2003-11-11 US claimed
JP-2003506355-A 2003-02-18 JP claimed
WO-2002062762-A2 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 WO claimed
EP-1198456-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2002-04-24 EP claimed
US-20020028836-A1 Potassium channel openers ABBVIE INC. 2002-03-07 US claimed
WO-2001009096-A2 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2001-02-08 WO claimed
EP-1392655-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2008-07-16 EP disclosed
EP-1198456-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2007-09-19 EP disclosed
US-6645968-B2 E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; ABBOTT LABORATORIES 2003-11-11 US disclosed
EP-1198456-A2 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2002-04-24 EP disclosed
US-20020028836-A1 Potassium channel openers ABBVIE INC. 2002-03-07 US disclosed
WO-2001009096-A2 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2001-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028836-A1 Potassium channel openers KCNJ2, KCNJ11, KCNJ1 ABCC9 359/4885ABCC8 451/4885KCNJ11 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.